New Horizons in HER2+ Breast Cancer: Pharmacist-Focused Strategies and Insights

Presented by Creative Educational Concepts, Inc. (CEC) and supported through independent educational grants from AstraZeneca and Daiichi Sankyo.

Target Audience

This activity is designed to meet the educational needs of oncology pharmacists, pharmacy directors, and pharmacy residents.

Learning Objectives

At the conclusion of this application-based activity, participants will be able to:

  1. Describe the molecular heterogeneity of breast cancer and review how novel treatment approaches such as antibody-drug conjugates (ADCs) are overcoming obstacles in the management of HER2+ disease.
  2. Examine the safety and efficacy profiles of currently-approved ADCs, both in breast cancer and across other malignancies, and evaluate emerging clinical data for agents in late-stage trials.
  3. Explore current guideline recommendations for the management of HER2+ breast cancer and identify key inflection points in the changing treatment paradigm, including resistance mitigation strategies, novel mechanisms, and toxicity prevention.
  4. Using a case-based format, assess challenging clinical questions related to the integration of ADCs into practice, and discuss adaptive ways the oncology pharmacist can optimize therapy, anticipate adverse events, and improve outcomes for patients. 
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 Participation
Course opens: 
04/13/2020
Course expires: 
04/13/2021
Rating: 
0

Val R. Adams, PharmD, FCCP, BCOP
University of Kentucky College of Pharmacy Markey Cancer Center 
Lexington, Kentucky

 

Dr. Adams is an Associate Professor in the Department of Pharmacy Practice and Science in the College of Pharmacy at the University of Kentucky. He is on the graduate faculty and is a member of the Markey Cancer Center where he has a clinical practice site. He co-chairs the protocol review and monitoring committee for the NCI Designated Markey Cancer Center. As the Director of the hematology/oncology residency program, he has trained 40 PGY2 oncology residents and maintains an active research program. He has trained two post-doctoral fellows, been the thesis advisor for 4 masters students, and served on 20 PhD dissertation student committees serving as advisor or co-advisor for 7 of them. He received his B.S. in Pharmacy from the University of Utah and received his Doctor of Pharmacy from the University of Texas at Austin jointly with the University of Texas Health Science Center at San Antonio. He completed a residency in hematology/oncology at the Audie L. Murphy Memorial V.A. Hospital in San Antonio, Texas. He then completed a two-year fellowship in immunology and transplantation at the University of Florida. Following the completion of the fellowship, he joined the University of Kentucky faculty in 1996.

 

Neelima Denduluri, MD
Virginia Cancer Specialists 
Reston, Virginia

 

Dr. Neelima Denduluri earned her Medical Degree from the Louisiana State University Medical Center, where she served as President of the American Medical Student Association. Upon graduation she received the “Exemplar of Desirable Attitudes of the Physician Towards His Patients” award, which is bestowed upon one graduating senior. She completed her Internal Medicine residency at Georgetown University Medical Center. During her fellowship at the National Cancer Institute, she was honored with the distinction of serving as Chief Fellow. She later served as Assistant Clinical Investigator and Staff Physician at NCI before joining Virginia Cancer Specialists.

Dr. Denduluri remains highly involved in the local community by participating in community outreach, speaking to support groups, and volunteering at the Arlington Free Clinic since 1999. She has consistently been named as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine, and she has been featured in both local and national media for her expertise in breast cancer.
In addition to her passion for patient care, Dr. Denduluri’s dedication to the advancement of medicine has led her to take on multiple leadership roles, including: Associate Chair of the US Oncology Breast Cancer Research Committee; Former Chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Committee and Current Member of the ASCO Education Committee; and Cancer Committee Chairman at Virginia Hospital Center. Dr. Denduluri also currently serves as an associate and principal investigator on many clinical trials, and is a steering committee member for NAPBC accreditation for the Reinsch Pierce Family Center for Breast Health.

Dr. Denduluri continues to be active in medical education, currently serving as Clinical Assistant Professor at Georgetown University Medical Center. She has also taught attending students and residents of Virginia Commonwealth University, as well as oncology fellows at the National Navel Medical Center in Bethesda, MD. Dr. Denduluri has published multiple articles and abstracts, and her work has been presented at various national meetings, including the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium.


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner: 
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters:

Val R. Adams, PharmD, FCCP, BCOP–has disclosed that he is a consultant for Amgen.

Neelima Denduluri, MD–has disclosed that she is a consultant for Daiichi Sankyo and Seattle Genetics. She receives grant/research support from Amgen, Daiichi Sankyo, Genentech, Immunomedics, Lilly, Novartis, Pfizer, Seattle Genetics, and Synthon.

Content Reviewer:

Jason Bergsbaken, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

CPE
This application-based activity is approved for 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-20-012-H01-P).

Other
Creative Educational Concepts, Inc. certifies this activity for 1.00 hour of participation.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

Adobe Flash Player